Alector moved into MBC BioLabs on the day we opened our doors, and now just over five years later they have two programs in the clinic, a partnership with AbbVie, and are now are preparing to go public. Alector set terms for its initial public offering, which would value the immuno-neurology company at about $1.4 billion!
Alector is developing therapeutics that harness the body’s immune cells power to target neurodegenerative diseases. The company’s lead drug candidate, AL001, is a therapeutic candidate for frontotemporal dementia carrying a progranulin (PGRN) loss-of-function mutation.